Skip to main content
Clinical Trials/NCT03050385
NCT03050385
Completed
Not Applicable

COgnitive REhabilitation During Transcranial Direct Current Stimulation for Major or Mild Neurocognitive Disorder Patients

National Center of Neurology and Psychiatry, Japan1 site in 1 country20 target enrollmentOctober 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Transcranial Direct Current Stimulation
Sponsor
National Center of Neurology and Psychiatry, Japan
Enrollment
20
Locations
1
Primary Endpoint
Attrition rate due to adverse events
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this study is to explore whether active transcranial direct current stimulation during cognitive rehabilitation tasks can boost cognitive enhancement without severe side effects in mild cognitive impairment or mild dementia patients.

Detailed Description

This study explores the additive effect of transcranial direct stimulation compared to sham stimulation during cognitive rehabilitation tasks in mild cognitive impairment or mild dementia patients. Potential participants are recruited by physicians' referral or self-entry. Informed consent by a clinical research coordinator and research physician is performed followed by screening. Participants who passed screening go through 10 sessions of active or sham transcranial direct current stimulation and are evaluated their cognitive function at screening, at the end, and two weeks after the intervention. For quality assurance, independent researcher regularly monitor and audit as participants are enrolled in the trial.

Registry
clinicaltrials.gov
Start Date
October 2016
End Date
August 18, 2017
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
National Center of Neurology and Psychiatry, Japan
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • participants with a diagnosis of either major neurocognitive disorder or mild neurocognitive disorder, defined in Diagnostic and Statistical Manual of Mental disorder (DSM-5)
  • taking the stable dose of psychotropic medication, such as cholinesterase inhibitors or NMDA(N-methyl-D-aspartate) receptor antagonist, for the past two weeks
  • ambulant by oneself with or without aiding devices.

Exclusion Criteria

  • with severe psychotic symptoms requiring antipsychotic treatment
  • with risks of hospitalization within 6 weeks because of severe depression and/or suicide ideation
  • clinically contraindicated to electroconvulsive therapy (ECT) or transcranial direct current stimulation (tDCS)
  • with the Mini-Mental State Examination (MMSE) score of less than 18 or the Clinical Dementia Rating Scale (CDR) score of more than 2,
  • unable to participate for more than 2 days during the trial
  • unable to write a sentence or copy a figure on MMSE at screening.

Outcomes

Primary Outcomes

Attrition rate due to adverse events

Time Frame: up to two weeks

Secondary Outcomes

  • difference of Clinical Dementia Rating scale - sum of boxes(up to four weeks)
  • difference of the mini mental state examination(up to four weeks)
  • Attrition rate for any reason(up to four weeks)
  • difference of Frontal Assessment Battery(up to four weeks)
  • difference of Alzheimer Disease Assessment Scale -Cognitive subscale(up to four weeks)
  • difference of Mini Mental State Examination(up to four weeks)

Study Sites (1)

Loading locations...

Similar Trials